lifestyle.pspl.com

Author: Zealand Pharma

Zealand Pharma announces Boehringer Ingelheim’s novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase 3 trial

May 6, 2026
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

May 5, 2026
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

May 5, 2026
Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2026

May 5, 2026
Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations

May 4, 2026
Total number of shares and voting rights in Zealand Pharma as of March 31, 2026

May 2, 2026
Zealand Pharma Establishes U.S. Research Hub in Cambridge, Massachusetts to Expand Drug Discovery Capabilities and Accelerate Medicine Creation

May 2, 2026
Zealand Pharma to participate in upcoming investor conferences in March 2026

May 2, 2026
Zealand Pharma increases its share capital as a result of the exercise of employee warrants

May 1, 2026
Zealand Pharma announces positive Phase 2 results for petrelintide, an amylin analog with potential to redefine the weight management experience for people living with overweight and obesity

April 28, 2026